Alkermes plc ( ALKS )
recently announced positive results from a phase I study on its new
antipsychotic candidate, ALKS 3831. ALKS 3831 is a combination of
ALKS 33, and Eli Lilly and Company 's ( LLY )
Alkermes is developing ALKS 3831 for the treatment of
schizophrenia and is designed to reduce the antipsychotic-related
metabolic side effect of weight gain. Alkermes enrolled 106 healthy
volunteers for the study.
Results from the study showed that weight gain in patients who
were administered ALKS 3831 was significantly lower (an average of
2.5 kg) than in patients who took Zyprexa (an average of 3.4 kg).
Alkermes also reported that ALKS 3831 was well tolerated in the
study and the safety and tolerability results were almost similar
to that of Zyprexa alone.
The company stated in its press release that weight gain is a
common side effect in atypical antipsychotic medications and
Zyprexa has the highest number of incidences and greatest amount of
weight gain in this class of drugs.
Alkermes expects to initiate a phase II study on ALKS 3831 in
mid-calendar 2013 after meeting the US Food and Drug Administration
(FDA) on the basis of the positive results from the phase I
We remind investors that the schizophrenia market is highly
competitive with the presence of players like Eli Lilly and
Novartis AG ( NVS
We currently have a Neutral recommendation on Alkermes. The
stock carries a Zacks #3 Rank (Hold). Meanwhile, other pharma
stocks such as Targacept, Inc. ( TRGT )
and Repligen Corporation ( RGEN )
carry a Zacks #1 Rank (Strong Buy).ALKERMES INC (ALKS): Free Stock Analysis ReportLILLY ELI & CO (LLY): Free Stock Analysis
ReportNOVARTIS AG-ADR (NVS): Free Stock Analysis
ReportREPLIGEN (RGEN): Free Stock Analysis ReportTARGACEPT INC (TRGT): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment